scispace - formally typeset
Open AccessJournal ArticleDOI

Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics.

TLDR
No evidence was found to suggest that the reduction in new ADHF events in SPRINT was due to differential diuretic use.
Abstract
Objectives This study assessed the potential role of differential diuretic drugs in preventing incident acute decompensated heart failure (ADHF) in the SPRINT (Systolic Blood Pressure Intervention Trial) study. Background SPRINT showed that intensive blood pressure reduction in older patients (50 to 97 years of age) resulted in 36% fewer incident cases of ADHF. However, some investigators have questioned whether this was due merely to intergroup differences in diuretic medications. Methods Detailed use of medication data prospectively collected throughout the trial were examined. Results ADHF events occurred in 173 of 9,361 participants. Diuretic medication increased in both arms from screening to baseline visit (from 45% to 50% in the standard arm; and from 43% to 63% in the intensive arm) and then remained steady. The lowest use of diuretic agents was among participants in the standard arm who never had an ADHF event. Withdrawal of diuretic agents at the baseline visit occurred in 6.1% (n = 284) of participants in the standard arm and 2.3% (n = 107) of participants in the intensive arm. Of these, only 11 developed ADHF during the trial (10 in the standard arm, 1 in the intensive arm), and only 1 occurred ≤1 month after diuretic withdrawal. The benefit of ADHF reduction remained significant even after excluding those 11 participants (hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.5 to 0.94; p = 0.02). Most ADHF events occurred in participants who were taking prescribed diuretic therapy at the last visit, prior to the ADHF event. There was limited use of loop ( Conclusions No evidence was found to suggest that the reduction in new ADHF events in SPRINT was due to differential diuretic use. (Systolic Blood Pressure Intervention Trial [SPRINT]; NCT01206062 ).

read more

Citations
More filters
Journal ArticleDOI

Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction

TL;DR: Focusing on the tremendous overlap of hypertensive heart disease with HFpEF, it is proposed that approaches currently used to guide therapies for hypertension be applied to the treatment ofHFpEF.
Journal ArticleDOI

Heart Failure Events in a Clinical Trial on Arterial Hypertension: New Insights Into the SPRINT Trial

TL;DR: In this paper, the SPRINT data were analyzed with a redefined composite end point including myocardial infarction, acute coronary syndrome other than mycardial infrction, stroke, and cardiovascular death (excluding heart failure events).
Journal ArticleDOI

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

TL;DR: The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive for heart failure in congestive failure with reduced ejection fraction.
References
More filters
Journal ArticleDOI

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

TL;DR: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure target of less than 120 mm Hg, as compared with less than 140 mm HG, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.
Related Papers (5)